Botanix (ASX:BOT) has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.

According to Botanix, the first prescriptions were quickly followed up by the first deliveries of products to patients; the move was also a confirmation of logistics between Botanix, telehealth partners, and its patients.

It’s given Botanix the chance to improve marketing and sales materials, per company statements, with a ‘sales force’ engaged and preparing for a launch meeting in late January.

The company ultimately pointed to its transition to a revenue-generating company ahead of the “full commercial launch” in Q1 2025.

“With less than 10 employees and contractors at the time of Sofdra approval, the Botanix team has now grown to 25,” the healthcare company wrote today.

“Drawing talent from leading dermatology and specialty pharmaceutical companies in the USA, with an average of over 20 years’ experience, the team is now fully staffed and readying for launch.”

In the company’s eyes, FDA approval was the gamechanger for the stock. And that’s reflected in the company’s share price. On a 1Y basis, BOT shares are up +153%.

BOT last traded at 38cps.

Join the discussion: See what HotCopper users are saying about Botanix and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.